000 | 05404cam a2200577Ma 4500 | ||
---|---|---|---|
001 | ocn911246573 | ||
003 | OCoLC | ||
005 | 20190328114811.0 | ||
006 | m o d | ||
007 | cr cnu---unuuu | ||
008 | 150620s2015 ne o 001 0 eng d | ||
040 |
_aEBLCP _beng _epn _cEBLCP _dOPELS _dE7B _dUIU _dUV0 _dOCLCF _dOCLCQ _dBUF _dOCLCO _dMERER _dOCLCO _dOCLCQ _dU3W _dOCLCO _dD6H _dUKMGB _dWYU _dOCLCO _dOCLCA |
||
015 |
_aGBB6G6316 _2bnb |
||
016 | 7 |
_a018086898 _2Uk |
|
020 | _z9780444626493 | ||
020 | _z0444626492 | ||
020 | _z9780444626677 | ||
020 | _z0444626670 | ||
035 | _a(OCoLC)911246573 | ||
050 | 4 | _aRC271.C5 | |
082 | 0 | 4 | _a616.994061 |
100 | 1 | _aAvenda�no, Carmen. | |
245 | 1 | 0 |
_aMedicinal chemistry of anticancer drugs / _h[electronic resource] _cby Carmen Avenda�no and J. Carlos Men�endez. |
250 | _a2nd ed. | ||
260 |
_aAmsterdam : _bElsevier Science, _c2015. |
||
300 | _a1 online resource (767 pages) | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
588 | 0 | _aPrint version record. | |
500 | _aIncludes index. | ||
520 | _aMedicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. | ||
505 | 0 | _aFront Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology. | |
505 | 8 | _a9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid. | |
505 | 8 | _a4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase. | |
505 | 8 | _a6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs. | |
505 | 8 | _a3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens. | |
650 | 0 |
_aCancer _xChemotherapy. |
|
650 | 0 |
_aDrugs _xDesign. |
|
650 | 0 | _aPharmaceutical chemistry. | |
650 | 7 |
_aCancer _xChemotherapy. _2fast _0(OCoLC)fst00845327 |
|
650 | 7 |
_aDrugs _xDesign. _2fast _0(OCoLC)fst00898790 |
|
650 | 7 |
_aPharmaceutical chemistry. _2fast _0(OCoLC)fst01060115 |
|
650 | 2 |
_aNeoplasms _xtherapy. _0(DNLM)D009369Q000628 |
|
650 | 2 |
_aDrug Design. _0(DNLM)D015195 |
|
650 | 2 |
_aChemistry, Pharmaceutical. _0(DNLM)D002626 |
|
655 | 4 | _aElectronic books. | |
700 | 1 |
_aMen�endez, J. Carlos _q(Jos�e Carlos) |
|
776 | 0 | 8 |
_iPrint version: _aAvendano, Carmen. _tMedicinal Chemistry of Anticancer Drugs. _dBurlington : Elsevier Science, �2015 _z9780444626493 |
856 | 4 | 0 |
_3ScienceDirect _uhttp://www.sciencedirect.com/science/book/9780444626493 |
999 |
_c247106 _d247106 |